SG11201510654WA - Stable intravenous formulation - Google Patents
Stable intravenous formulationInfo
- Publication number
- SG11201510654WA SG11201510654WA SG11201510654WA SG11201510654WA SG11201510654WA SG 11201510654W A SG11201510654W A SG 11201510654WA SG 11201510654W A SG11201510654W A SG 11201510654WA SG 11201510654W A SG11201510654W A SG 11201510654WA SG 11201510654W A SG11201510654W A SG 11201510654WA
- Authority
- SG
- Singapore
- Prior art keywords
- intravenous formulation
- stable intravenous
- stable
- formulation
- intravenous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361838642P | 2013-06-24 | 2013-06-24 | |
US201361840930P | 2013-06-28 | 2013-06-28 | |
PCT/EP2014/062982 WO2014206866A1 (en) | 2013-06-24 | 2014-06-20 | Stable intravenous formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201510654WA true SG11201510654WA (en) | 2016-01-28 |
Family
ID=51014281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201510654WA SG11201510654WA (en) | 2013-06-24 | 2014-06-20 | Stable intravenous formulation |
Country Status (15)
Country | Link |
---|---|
US (2) | US20160136280A1 (en) |
EP (1) | EP3013316B1 (en) |
JP (1) | JP6346945B2 (en) |
KR (1) | KR20160011668A (en) |
CN (1) | CN105338959A (en) |
AR (1) | AR096710A1 (en) |
AU (1) | AU2014301324A1 (en) |
BR (1) | BR112015029976A2 (en) |
CA (1) | CA2913174A1 (en) |
HK (1) | HK1214531A1 (en) |
MX (1) | MX2015017654A (en) |
RU (1) | RU2015154097A (en) |
SG (1) | SG11201510654WA (en) |
WO (1) | WO2014206866A1 (en) |
ZA (1) | ZA201508641B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3498712B1 (en) * | 2016-08-08 | 2024-01-03 | Jiangsu Yayo Biotechnology Co. Ltd | Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof |
GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
JP2023539867A (en) | 2020-08-27 | 2023-09-20 | 大塚製薬株式会社 | Biomarkers for cancer treatment using MDM2 antagonists |
GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08157491A (en) * | 1994-11-30 | 1996-06-18 | Hayashibara Biochem Lab Inc | Production of trehalose derivative |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
AU2003293195A1 (en) * | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
JP5490714B2 (en) * | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | Protein preparation |
US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
EA032840B8 (en) * | 2011-06-22 | 2020-06-18 | Вайоми Терапеутикс Лимитед | Conjugate-based antifungal prodrugs and use thereof |
JP2013018737A (en) * | 2011-07-11 | 2013-01-31 | Fujifilm Corp | Freeze-dried preparation and method for producing the same |
US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
-
2014
- 2014-06-20 CA CA2913174A patent/CA2913174A1/en not_active Abandoned
- 2014-06-20 JP JP2016520502A patent/JP6346945B2/en not_active Expired - Fee Related
- 2014-06-20 RU RU2015154097A patent/RU2015154097A/en not_active Application Discontinuation
- 2014-06-20 WO PCT/EP2014/062982 patent/WO2014206866A1/en active Application Filing
- 2014-06-20 KR KR1020157036457A patent/KR20160011668A/en not_active Application Discontinuation
- 2014-06-20 CN CN201480035359.0A patent/CN105338959A/en active Pending
- 2014-06-20 SG SG11201510654WA patent/SG11201510654WA/en unknown
- 2014-06-20 US US14/898,122 patent/US20160136280A1/en not_active Abandoned
- 2014-06-20 BR BR112015029976A patent/BR112015029976A2/en not_active IP Right Cessation
- 2014-06-20 AU AU2014301324A patent/AU2014301324A1/en not_active Abandoned
- 2014-06-20 MX MX2015017654A patent/MX2015017654A/en unknown
- 2014-06-20 EP EP14732865.2A patent/EP3013316B1/en not_active Not-in-force
- 2014-06-24 AR ARP140102375A patent/AR096710A1/en unknown
-
2015
- 2015-11-24 ZA ZA2015/08641A patent/ZA201508641B/en unknown
-
2016
- 2016-03-08 HK HK16102619.9A patent/HK1214531A1/en unknown
-
2017
- 2017-10-24 US US15/791,593 patent/US20180071393A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180071393A1 (en) | 2018-03-15 |
RU2015154097A (en) | 2017-07-26 |
BR112015029976A2 (en) | 2017-07-25 |
CA2913174A1 (en) | 2014-12-31 |
WO2014206866A1 (en) | 2014-12-31 |
US20160136280A1 (en) | 2016-05-19 |
EP3013316B1 (en) | 2018-05-30 |
EP3013316A1 (en) | 2016-05-04 |
AU2014301324A1 (en) | 2015-12-10 |
MX2015017654A (en) | 2016-04-15 |
HK1214531A1 (en) | 2016-07-29 |
JP2016522239A (en) | 2016-07-28 |
KR20160011668A (en) | 2016-02-01 |
AR096710A1 (en) | 2016-01-27 |
JP6346945B2 (en) | 2018-06-20 |
ZA201508641B (en) | 2017-09-27 |
CN105338959A (en) | 2016-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3065716C0 (en) | Formulations | |
GB201307385D0 (en) | Syringes | |
HRP20180684T1 (en) | Drug combination | |
HK1221790A1 (en) | Utility application delivery platform | |
ZA201506252B (en) | Syringe | |
HK1218076A1 (en) | Stabilized pemetrexed formulation | |
GB201319792D0 (en) | Formulations | |
HK1214951A1 (en) | Ophthalimic formulations | |
GB201320432D0 (en) | Novel formulation | |
ZA201505515B (en) | Liquid menthol compositions | |
PT3060256T (en) | A novel stable formulation | |
HK1214531A1 (en) | Stable intravenous formulation | |
GB201408677D0 (en) | Syringes | |
GB201322948D0 (en) | Improved formulation | |
EP2978473A4 (en) | Auto-retractible syringe | |
HUP1300496A2 (en) | Stable pharmaceutical composition | |
GB2517232B (en) | Formulation | |
GB201317718D0 (en) | Novel formulation | |
IL244316A0 (en) | Novel drug formulation | |
HK1209981A1 (en) | Formulation | |
GB201312347D0 (en) | Formulation | |
GB201317717D0 (en) | Novel formulation | |
GB201320786D0 (en) | Medicament | |
GB201313909D0 (en) | Powder formulation | |
GB201304146D0 (en) | Powder formulation |